DDInter1675 DDInter1658
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Simvastatin {u} (Compound) treats {v} (Disease) atherosclerosis
Simvastatin {u} (Compound) binds {v} (Gene) ABCC2
Simvastatin {u} (Compound) upregulates {v} (Gene) ANKRD10
Simvastatin {u} (Compound) downregulates {v} (Gene) PNP
Simvastatin {u} (Compound) causes {v} (Side Effect) Cataract
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liothyronine
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon alfacon-1
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Simvastatin (Compound) treats atherosclerosis (Disease)
Simvastatin (Compound) binds ABCC2 (Gene)
Simvastatin (Compound) upregulates ANKRD10 (Gene)
Simvastatin (Compound) downregulates PNP (Gene)
Simvastatin (Compound) causes Cataract (Side Effect)
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Liothyronine
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1
Simvastatin may lead to a major life threatening interaction when taken with Colchicine